Omaveloxolone in a real-world setting: implications in Friedreich Ataxia beyond the classic study population
Objective: The aim was to monitor safety and efficacy of omaveloxolone treatment in a single center real life cohort, focusing on Friedreich Ataxia (FRDA) patients…Dual device-aided therapy in advanced Parkinson’s Disease: combining bilateral deep brain stimulation and continuous subcutaneous foslevodopa/foscarbidopa Infusion
Objective: To describe our experience with dual device-aided therapies (DATs). Background: DATs for advanced Parkinson's disease (PD) include deep brain stimulation, continuous subcutaneous apomorphine infusion…Disparate Subregional Striatal DAT-SPECT Associations with CSF-Synucleinopathy Status and Clinical Severity Across Parkinson’s Disease Continuum
Objective: To determine the association between subregional DAT binding ratios (SBRs) for disease risk, PD progression, and whether these associations differ based on SAA status.…Evaluating Gene-Environment Interactions between Head Injury and Parkinson’s Disease Risk Variants.
Objective: To evaluate gene-environment interactions between head injury and candidate single nucleotide polymorphisms (SNP) in Parkinson’s disease (PD). Background: Head injury is consistently associated with…Neuromelanin Loss Is Associated with Increased Substantia Nigra Free-Water: a Longitudinal Study of Controls, RBD, and PD
Objective: To longitudinally characterize substantia nigra (SN) neuromelanin (NM) and free-water (FW) MRI biomarkers by comparing control, REM sleep behaviour disorder (RBD), and Parkinson’s disease…Ferritin as a factor in the examination of Parkinson’s disease and Progressive Supranuclear Palsy
Objective: The goal of this study is to analyze the possible significance of serum ferritin levels in the examination of Parkinson’s disease (PD) and Progressive…Mechanistic study of PARP9-mediated mitochondrial transfer in regulating dopaminergic neuronal injury and neuroinflammation in Parkinson’s disease
Objective: To investigate PARP9 expression and localization in PD models, evaluate its effects on dopaminergic neuronal injury and microglial activation, and determine whether PARP9 regulates…The Global Parkinsons Genetics Program: Expanding the Diversity of Neurological Disorder Data – 2026 Update
Objective: To broaden the available data for Parkinson's Disease (PD) and related disorders by integrating genetic data from more than 140,000 participants worldwide through genotyping…Genomic Insights into Parkinson’s Disease: LARGE-PD and PD GENEration Collaboration in El Salvador
Objective: To characterize clinical and genetic features of Parkinson’s disease (PD) in El Salvador in the PD GENEration and LARGE-PD. Background: Central American populations remain…Exploring the Relationship Between Insomnia and Autonomic Dysfunction in Parkinson’s Disease: A 1 Year SCOPA-AUT Analysis
Objective: To evaluate the progression of autonomic dysfunction over one year in patients with Parkinson’s disease (PD) with and without comorbid insomnia. Background: Insomnia and…
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 208
- Next Page »